A novel PEGylated recombinant alpha-galactosidase produced in plant cells, pegunigalsidase alfa, was approved in 2023 by the FDA and EMA for intravenous administration at the dose of 1 mg/kg every other week in AFD adult patients. Here, GLA is linked to Nager acrofacial dysostosis.